Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report released on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Stock Down 1.1 %

Shares of NASDAQ:NERV opened at $1.82 on Friday. Minerva Neurosciences has a fifty-two week low of $1.77 and a fifty-two week high of $9.40. The firm’s 50-day simple moving average is $2.18 and its 200-day simple moving average is $2.42. The company has a market cap of $12.73 million, a price-to-earnings ratio of -4.14 and a beta of 0.12.

Institutional Trading of Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC grew its stake in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,764 shares of the biopharmaceutical company’s stock after acquiring an additional 8,525 shares during the period. Citadel Advisors LLC owned about 0.37% of Minerva Neurosciences worth $57,000 at the end of the most recent reporting period. 34.56% of the stock is owned by institutional investors and hedge funds.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.